BioSpace News Archive

BioSpace takes a look at the annual compensation for the chief executive officers of vaccine developers.

Dental braces are commonly used in orthodontist treatment in order to fix malocclusion and jaw problems. Dental braces are used for providing proper alignment to teeth; they are custom-based devices used for keeping pressure on the teeth to straighten them over a period of time.

Electronic medical record systems, sometimes used synonymously with electronic health records systems, have gained widespread traction in medical practices across the globe.

Microbial identification has become an important aspect of the overall healthcare domain. With the growing prevalence of infectious diseases, increasing frequency of global pandemic, and rising food safety concerns the need for rapid and reliable microbial identification has become highly important.

A number of methods in cell lysis market are used for cell lysis or cell fractionation, which mainly consist of disintegration of cell membranes partially or fully to obtain inter-cellular materials.

Cellectis S.A., a clinical-stage biotechnological company employing its core proprietary technologies to develop best-in-class products based on gene-edited allogeneic CAR T-cells in the field of immuno-oncology, announced that it has completed sales of approximately $47 million of American Depositary Shares pursuant to the Company’s ATM program established on March 29, 2021, through Jefferies LLC, acting as sales agent.

Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces that the company’s Board of Directors has approved the procedure for holding a Combined General Meeting behind closed doors on Tuesday, May 18, 2021.

Bionomics Limited has completed its 1 for 6 pro rata non–renounceable entitlement offer that was announced on 8 March 2021 and concurrent placement that was announced on 17 March 2021 which collectively raised approximately A$22.9 million.

Bold Therapeutics, a clinical-stage biopharmaceutical company developing BOLD-100, a first-in-class anti-cancer agent, announced that Sandra Van Schaeybroeck, PhD (Queen’s University Belfast) will be presenting research supporting BOLD-100 as a potential anti-resistance therapy for difficult-to-treat cancers

IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQB:IGXT) (“ IntelGenx ”), a leader in pharmaceutical films, today announced that it is proposing to amend the terms of its 6.0% convertible unsecured promissory notes due June 1, 2021, originally issued by private placement on May 8, 2018